Satellos Bioscience Inc.

TSX:MSCL.TO

Biotechnology

Healthcare
$8.62 +0.12%

+$0.01 today

Market cap
$182.89M
Beta
1.17
P/E (TTM)
-1.8
EPS (TTM)
-$0.32
52W Low $6.36High $18.98

Volume 0.01M

Average 0.02M

MSCL.TO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Satellos Bioscience Inc.TSX: MSCL.TO

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 43.4% from a year ago

Cash & equivalents stood at $18.71M at the end of Q1 FY2026, down 43.4% from a year earlier and up 91.2% from the prior quarter. Over 3 fiscal years it compounded at +72.0% a year.

Context

  • Cash & equivalents amounted to 24.9% of total assets at the end of Q1 FY2026, down 49.6 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -43.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.71M+91.2% QoQ
Last fiscal yearDec 2025
$9.79M-83.0% YoY
Year agoMar 2025
$33.05M-43.4% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.4%——
1 year-83.0%——
3-year CAGR+72.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

Mixed currencies · from the balance sheet

Latest · FY2025
9.79M USD
Year-over-year change
—

Cash & Equivalents vs competitors

How MSCL.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -43.4% is the 3rd highest of 4, against a peer median of +18.8%.
  • Cash & equivalents amounts to 24.9% of total assets for MSCL.TO, versus a peer median of 68.6%.
MSCL.TO Competitors
Cash & Equivalents for MSCL.TO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CRDL.TOCardiol Therapeutics Inc.Mar 2026CA$27.67M CAD+18.8%-28.9%88.1%
MSCL.TOSatellos Bioscience Inc.Mar 2026$18.71M USD-43.4%+72.0%24.9%
HBP.TOHelix BioPharma Corp.Apr 2026CA$2.84M CAD+297.5%-72.9%13.3%
SVA.TOSernova Corp.Apr 2026CA$1.05M CAD-47.3%-58.8%68.6%
Peer median (excluding MSCL.TO) —+18.8%-58.8%68.6%

Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · CAD
FY2024
Dec 2024 · CAD
FY2025
Dec 2025 · USD
Cash & Equivalents4.87M1.92M22.07M57.66M9.79M
Short-term Investments0017.52M12.2M17.87M
Net Receivables527.98K260.44K583K626K369.33K
Inventory00000
Other Current Assets02.57K4K0(6.92K)
Total Current Assets5.44M2.23M40.32M73.01M31.83M
Property, Plant & Equipment (Net)8.19K9K19K5K4.99K
Goodwill0(190)000
Intangible Assets7.14M3.92M3.92M00
Long-term Investments042K41K00
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets7.14M3.97M3.98M5K4.99K
Total Assets12.59M6.2M44.3M73.02M31.83M
Account Payables1.13M1.47M1.04M2.97M1.77M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities0000(7.47K)
Total Current Liabilities2.1M2.83M3.62M5.16M4.1M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities00000
Total Liabilities2.1M2.83M3.62M5.16M4.1M
Common Stock28.32M30.21M61.92M105.73M85.67M
Retained Earnings(20.29M)(31.61M)(47.5M)(75.6M)(81.82M)
Accumulated OCI(1.44K)1.09M21.24M(217K)13.73M
Other Stockholders Equity00027.62M0
Minority Interest00000
Total Equity10.48M3.37M40.67M67.86M27.73M
Total Debt00000
Net Debt(4.87M)(1.92M)(22.07M)(57.66M)(9.79M)

Satellos Bioscience Inc.

TSX:MSCL.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.